Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59

Immunotherapy using MoAbs is inefficient due to limited activation of human effectors by mouse antibodies and multiple protective mechanisms available to host cells against autologous complement. We have used chemically engineered antibody constructs and human complement in vitro to specifically tar...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: HARRIS, C L, KAN, K S, STEVENSON, G T, MORGAN, B P
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Science Inc 1997
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1904584/
https://ncbi.nlm.nih.gov/pubmed/9030877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2249.1997.265-ce1156.x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky